Let’s build mRNA vaccine formulation and manufacturing capability locally in Australia
17 Dec, 2020 | Newsletters
A new age of mRNA vaccine development upon us. As a COVAX member, Australia will have access to buy and distribute mRNA vaccines if successful in clinical trials, and could also license the technology to make the vaccines domestically. But currently, Australia does not have the capacity to manufacture clinical-grade mRNA vaccines. A promising solution is the Precision Nanosystems Inc (PNI) NanoAssemblr platform that enables the rapid, reproducible and scalable manufacture of next-generation nanoparticle formulations of gene therapies, vaccines, and targeted medicines that use lipid nanoparticles and liposomes to encapsulate a payload such as a self-amplifying mRNA. Malvern Panalytical has partnered with Precision Nanosystems to show you the technologies that accelerate the large-scale production of nanoparticles, safely and cost-effectively. Watch the recent webinar “How to scale liposomal formulations for large-scale production: From benchtop to GMP manufacturing” Contact us for more information Nanoassemblr Ignite mRNA Vaccine Demo. The Ignite with NxGen Technology is the go-to for nanomedicine development for over 200 biopharma companies, bringing the latest innovations developed for the cGMP system to the bench — saving time and money. WATCH DEMO NOW Nanoassemblr Blaze mRNA Vaccine Demo. Using the NanoAssemblr Blaze, process development can be conducted from material preparation to buffer exchange, filtering and analytics, to ensure that a program is ready to quickly accelerate to the clinic. WATCH DEMO NOW Nanoassemblr GMP mRNA Vaccine Demo. Configurable & modular system with continuous flow enables manufacturing scales 200ml to greater than 100L. Fully disposable fluid path reduces risk and cost and QMS system compliant with cGMP requirements. WATCH DEMO NOW How it Works: PNI’s Microfluidic Platform is a Leap Forward in Manufacturing CONTACT US FOR YOUR DEMO ONSITE |